155 related articles for article (PubMed ID: 17116939)
1. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
Adès L; Chevret S; Raffoux E; de Botton S; Guerci A; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Maloisel F; Deconinck E; Ferrant A; Thomas X; Fegueux N; Chomienne C; Dombret H; Degos L; Fenaux P;
J Clin Oncol; 2006 Dec; 24(36):5703-10. PubMed ID: 17116939
[TBL] [Abstract][Full Text] [Related]
2. [Clinical effect of the SCMC APL-2010 regimen in treatment of acute promyelocytic leukemia in children: an analysis of 44 cases].
Wang Z; Shen SH; Tang YJ; Xue HL; Hu WT; Pan C; Tang JY; Gu LJ; Chen J
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Nov; 21(11):1073-1078. PubMed ID: 31753087
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive chemotherapy in induction therapy plays a key role in the prognosis of patients with low-risk acute promyelocytic leukaemia.
Zhu X; Tang F; Yu W; Zhao X; Qin Y; Jiang Q; Huang X; Jiang H
J Cell Mol Med; 2024 May; 28(10):e18252. PubMed ID: 38766688
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acute promyelocytic leukemia with high white cell blood counts.
Kelaidi C; Adès L; Fenaux P
Mediterr J Hematol Infect Dis; 2011; 3(1):e2011038. PubMed ID: 22084652
[TBL] [Abstract][Full Text] [Related]
5. Acute promyelocytic leukemia in children cancer hospital Egypt.
Semary S; Hammad M; Yassin D; El Sharkawy N; Soliman S; Salem S; Ezzat E; Mosa A; Ahmed S
Discov Oncol; 2024 Jun; 15(1):223. PubMed ID: 38861104
[TBL] [Abstract][Full Text] [Related]
6. Dynamic changes and multiplication rate of white blood cell count may direct the timing of cytoreduction chemotherapy during induction treatment in newly diagnosed acute promyelocytic leukemia with low-intermediate risk.
Wen J; Xu F; Zhou Q; Hu H; Liu Y; Su J; Zhang Y; Qu W; Shi L
Mol Clin Oncol; 2021 Jun; 14(6):112. PubMed ID: 33903818
[TBL] [Abstract][Full Text] [Related]
7. Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia.
Wu L; Chatla S; Lin Q; Chowdhury FA; Geldenhuys W; Du W
Nat Commun; 2021 Nov; 12(1):6936. PubMed ID: 34836965
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Sanz MA; Montesinos P; Rayón C; Holowiecka A; de la Serna J; Milone G; de Lisa E; Brunet S; Rubio V; Ribera JM; Rivas C; Krsnik I; Bergua J; González J; Díaz-Mediavilla J; Rojas R; Manso F; Ossenkoppele G; González JD; Lowenberg B;
Blood; 2010 Jun; 115(25):5137-46. PubMed ID: 20393132
[TBL] [Abstract][Full Text] [Related]
9. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.
Adès L; Sanz MA; Chevret S; Montesinos P; Chevallier P; Raffoux E; Vellenga E; Guerci A; Pigneux A; Huguet F; Rayon C; Stoppa AM; de la Serna J; Cahn JY; Meyer-Monard S; Pabst T; Thomas X; de Botton S; Parody R; Bergua J; Lamy T; Vekhoff A; Negri S; Ifrah N; Dombret H; Ferrant A; Bron D; Degos L; Fenaux P
Blood; 2008 Feb; 111(3):1078-84. PubMed ID: 17975017
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
Powell BL; Moser B; Stock W; Gallagher RE; Willman CL; Stone RM; Rowe JM; Coutre S; Feusner JH; Gregory J; Couban S; Appelbaum FR; Tallman MS; Larson RA
Blood; 2010 Nov; 116(19):3751-7. PubMed ID: 20705755
[TBL] [Abstract][Full Text] [Related]
12. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
Lo-Coco F; Avvisati G; Vignetti M; Breccia M; Gallo E; Rambaldi A; Paoloni F; Fioritoni G; Ferrara F; Specchia G; Cimino G; Diverio D; Borlenghi E; Martinelli G; Di Raimondo F; Di Bona E; Fazi P; Peta A; Bosi A; Carella AM; Fabbiano F; Pogliani EM; Petti MC; Amadori S; Mandelli F;
Blood; 2010 Oct; 116(17):3171-9. PubMed ID: 20644121
[TBL] [Abstract][Full Text] [Related]
13. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ; Bradstock K; Supple SG; Catalano A; Collins M; Hertzberg M; Browett P; Grigg A; Firkin F; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Blood; 2012 Aug; 120(8):1570-80; quiz 1752. PubMed ID: 22715121
[TBL] [Abstract][Full Text] [Related]
14. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.
Adès L; Guerci A; Raffoux E; Sanz M; Chevallier P; Lapusan S; Recher C; Thomas X; Rayon C; Castaigne S; Tournilhac O; de Botton S; Ifrah N; Cahn JY; Solary E; Gardin C; Fegeux N; Bordessoule D; Ferrant A; Meyer-Monard S; Vey N; Dombret H; Degos L; Chevret S; Fenaux P;
Blood; 2010 Mar; 115(9):1690-6. PubMed ID: 20018913
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients.
Adès L; Chevret S; Raffoux E; Guerci-Bresler A; Pigneux A; Vey N; Lamy T; Huguet F; Vekhoff A; Lambert JF; Lioure B; de Botton S; Deconinck E; Ferrant A; Thomas X; Quesnel B; Cassinat B; Chomienne C; Dombret H; Degos L; Fenaux P;
Am J Hematol; 2013 Jul; 88(7):556-9. PubMed ID: 23564205
[TBL] [Abstract][Full Text] [Related]
16. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
Faderl S; Thomas DA; O'Brien S; Ravandi F; Garcia-Manero G; Borthakur G; Ferrajoli A; Verstovsek S; Ayoubi M; Rytting M; Feliu J; Kantarjian HM
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):54-9. PubMed ID: 21454191
[TBL] [Abstract][Full Text] [Related]
17. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.
Avvisati G; Lo-Coco F; Paoloni FP; Petti MC; Diverio D; Vignetti M; Latagliata R; Specchia G; Baccarani M; Di Bona E; Fioritoni G; Marmont F; Rambaldi A; Di Raimondo F; Kropp MG; Pizzolo G; Pogliani EM; Rossi G; Cantore N; Nobile F; Gabbas A; Ferrara F; Fazi P; Amadori S; Mandelli F;
Blood; 2011 May; 117(18):4716-25. PubMed ID: 21385856
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
19. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group.
Fenaux P; Le Deley MC; Castaigne S; Archimbaud E; Chomienne C; Link H; Guerci A; Duarte M; Daniel MT; Bowen D
Blood; 1993 Dec; 82(11):3241-9. PubMed ID: 8241496
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
Coutre SE; Othus M; Powell B; Willman CL; Stock W; Paietta E; Levitan D; Wetzler M; Attar EC; Altman JK; Gore SD; Maher T; Kopecky KJ; Tallman MS; Larson RA; Appelbaum FR
Br J Haematol; 2014 May; 165(4):497-503. PubMed ID: 24528179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
